Treatment of basal cell carcinoma with intralesional recombinant interferons

Kowalzick, L.; Rogozinski, T.; Schöber, Christian; Fierlbeck, Gerhard; Mensing, H.; Jabłońska, Stefania; Remy, W.; Rassner, G.; Stetter, C.; Brzoska, J.

doi:10.1097/00008390-199309002-00093

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intralesional interferon beta and gamma have been used to treat BCC. [28][29][30][31] Table IV summarizes the characteristics of the studies using intralesional interferon.…”

Section: Interferonmentioning

confidence: 99%

“…Intralesional interferon beta has been used to treat 202 BCCs. 28,29 The sites of the tumors were not specified. Pretreatment biopsy was done in all patients.…”

Section: Bcc and Interferon Alfamentioning

confidence: 99%

“…Recurrences occurred in 5 tumors CR at 6 months (two), 1 year (two), and 2 years (one). 28,29 Laboratory monitoring (Table V) was done for all patients and none had ''significant'' laboratory changes. The outcome was judged to be good to excellent and without scarring aside from prior biopsy sites.…”

Section: Bcc and Interferon Alfamentioning

confidence: 99%

See 2 more Smart Citations

Intralesional chemotherapy for nonmelanoma skin cancer: A practical review

Kirby¹,

Miller²

2010

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…Intralesional interferon beta and gamma have been used to treat BCC. [28][29][30][31] Table IV summarizes the characteristics of the studies using intralesional interferon.…”

Section: Interferonmentioning

confidence: 99%

“…Intralesional interferon beta has been used to treat 202 BCCs. 28,29 The sites of the tumors were not specified. Pretreatment biopsy was done in all patients.…”

Section: Bcc and Interferon Alfamentioning

confidence: 99%

See 1 more Smart Citation

Intralesional chemotherapy for nonmelanoma skin cancer: A practical review

Kirby¹,

Miller²

2010

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…Several IFNs (IFN alpha (α)‐2, IFN α‐2a, IFN α‐2b, IFN beta (β), and IFN gamma (γ)) have been studied in the treatment of NMSC. Twenty‐five studies met the inclusion criteria for this review.…”

Section: Methodsmentioning

confidence: 99%

Topical and Intralesional Treatment of Nonmelanoma Skin Cancer: Efficacy and Cost Comparisons

Chitwood

Etzkorn

Cohen

2013

Dermatologic Surgery

View full text Add to dashboard Cite

show abstract

“…Using IFN‐β, remission rates between 50% and 100% were reported (Table 2), with an advantage in that the total dose inducing complete remission in BCC was lower for IFN‐β than IFN‐α, and that the side effects were less frequent 35. Available data on the use of IFN‐γ in BCC treatment are somewhat contradictory, with no cure rate above 50% (Table 2) and frequent side effects 36, 37.…”

Section: Current Treatment Approachesmentioning

confidence: 99%

Immunotherapy for nonmelanoma skin cancer

Urosevic

Dummer

2002

Cancer

View full text Add to dashboard Cite

BACKGROUNDBasal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin are the most common malignancies in the white human population, accounting for greater than 95% of nonmelanoma skin cancers (NMSCs). Current data show an increasing incidence of NMSC in recent decades. Although the mortality is low, this cancer group is associated with substantial morbidity. Multiple treatment modalities are available for NMSC, with surgery being a “cornerstone” of current therapy approaches. However, in patients with multiple lesions or in cases of tumors on critical locations, disfigurement and the disease recurrence may represent a serious problem associated with the surgical treatment. The purpose of this study was to review and analyze whether NMSC could represent a target for immune therapy, evaluating the aspects of the availability of tumor antigens and the existence of tumor specific immune response, including a summary of the major clinical studies dealing with immunotherapy for NMSC.METHODSThe authors have reviewed the available medical literature on NMSC, with a focus on tumor immunology and associated abnormalities, as well as immunotherapy‐based treatment trials.RESULTSThe major advantage of NMSCs is that they arise from the skin, which makes them easily detectable and treatable. Furthermore, these tumors posses all the prerequisites, i.e., the presence of tumor‐associated antigens as well as the tumor specific immune response, needed for immune intervention. This also was confirmed in various studies demonstrating clinical efficacy of cytokines and other immune response modifiers.CONCLUSIONSIn addition to clinical cure, by activating and stimulating patient's immune resources this therapeutic option may be a “silver bullet,” providing a long‐term protective immunity against initial tumor. Cancer 2002;94:477–85. © 2002 American Cancer Society.

show abstract

Treatment of basal cell carcinoma with intralesional recombinant interferons

Cited by 4 publications

References 0 publications

Intralesional chemotherapy for nonmelanoma skin cancer: A practical review

Intralesional chemotherapy for nonmelanoma skin cancer: A practical review

Topical and Intralesional Treatment of Nonmelanoma Skin Cancer: Efficacy and Cost Comparisons

Immunotherapy for nonmelanoma skin cancer

Contact Info

Product

Resources

About